0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast to 2030- Product Image
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast to 2030- Product Image
Sale

Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010626
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer monoclonal antibodies market is witnessing a surge in adoption due to major breakthroughs in precision oncology, shifting regulatory frameworks, and intensifying global competition. Senior leaders navigating investment and operational decisions will find informed guidance in this comprehensive analysis, which focuses on actionable insights and trends shaping the sector.

Market Snapshot: Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies Market grew from USD 78.60 billion in 2024 to USD 88.89 billion in 2025. It is expected to continue growing at a CAGR of 12.98%, reaching USD 163.49 billion by 2030. This expansion is driven by advancements in targeted therapies, broader clinical applications, and evolving reimbursement policies, placing monoclonal antibodies at the forefront of modern oncology treatment paradigms.

Cancer Monoclonal Antibodies Market: Scope & Segmentation

This report delivers in-depth coverage across the critical sub-segments and technologies shaping the global monoclonal antibody market for cancer therapies.

  • Mechanism of Action: Antibody drug conjugates, bispecific antibodies, checkpoint inhibitors, and radioimmunotherapy, including methods involving DNA alkylating agents, microtubule inhibitors, dual checkpoint modulators, T cell engagers, CTLA-4, PD-1, PD-L1, alpha emitters, and beta emitters.
  • Target Antigens: Major targets such as CD20, HER2, PD-1/PD-L1, and VEGF, which are driving both therapeutic advances and commercial differentiation.
  • Antibody Types: Chimeric, fully human, humanized, and murine constructs, each presenting differing immunogenicity and manufacturing considerations.
  • Therapeutic Indications: Focus areas include breast cancer, colorectal cancer, lung cancer, and lymphoma, reflecting evolving clinical standards and patient population needs.
  • Route of Administration: Intravenous and subcutaneous formulations aimed at optimizing patient convenience and resource use.
  • End Users: Cancer research centers, contract research organizations, hospitals, and specialty clinics leading clinical adoption and trials.
  • Formulation Options: Liquid and lyophilized powder formats tailored for stability, logistic efficiency, and on-site readiness.
  • Regional Landscape: Americas (including United States, Canada, Mexico, Brazil, Argentina, and key US states), Europe, Middle East & Africa (encompassing major and emerging healthcare markets), and Asia-Pacific (with countries such as China, India, Japan, Australia, and others significantly bolstering regional capacity).
  • Leading Companies: Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Novartis AG, Eli Lilly and Company, Sanofi S.A., Daiichi Sankyo Company, Limited.

Key Takeaways for Senior Decision-Makers

  • Ongoing innovations in antibody drug conjugates and bispecific structures are rapidly expanding the spectrum of precision cancer therapeutics.
  • The trend toward combination treatments and personalized therapeutic strategies underpins competitive differentiation in product portfolios.
  • Collaborative partnerships between pharmaceutical companies, biotechnology firms, and contract research organizations are accelerating clinical timelines and risk-sharing.
  • Regional investment in advanced manufacturing and regulatory reforms is enhancing both supply chain resilience and market access, especially in Asia-Pacific and the Americas.
  • Shifting preferences toward patient-centric delivery modes and digital diagnostics reflect a broader shift in healthcare resource optimization, impacting adoption rates.
  • Growing biosimilar competition is prompting manufacturers to invest in next-generation antibodies and novel modalities to preserve market share and address evolving patent landscapes.

Tariff Impact on Market Dynamics

New U.S. import tariffs introduced in 2025 have increased complexity in the global supply chain for cancer monoclonal antibodies. Input costs have risen due to tariffs on raw materials and reagents, prompting manufacturers to recalibrate sourcing strategies and explore domestic or tariff-exempt production. This adjustment is reshaping service agreements with contract research and clinical supply organizations, influencing pricing structures and potentially extending development timelines. Regulatory bodies continue to prioritise uninterrupted access to therapeutic innovations while organizations balance trade compliance with operational resilience.

Methodology & Data Sources

Analysis combines in-depth secondary research—covering peer-reviewed literature, regulatory filings, and industry publications—with primary insights from structured interviews with oncology experts and industry executives. Quantitative data were drawn from public financial disclosures and clinical trial registries, while qualitative findings were validated through expert panels for accuracy and strategic relevance.

Why This Report Matters

  • Equips senior decision-makers with strategic insight to guide investment, M&A, and operational plans in a dynamic oncology market landscape.
  • Provides comprehensive segmentation to support targeted portfolio development, geographic expansion, and technology adoption strategies.
  • Highlights emerging risks and opportunities in supply chains, regulatory policies, and competitive dynamics, enabling proactive decision-making.

Conclusion

The cancer monoclonal antibodies market is undergoing swift transformation, defined by persistent innovation and evolving global trade conditions. Leaders who leverage these insights will be well-positioned to drive success and capture value in the changing oncology therapeutics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Monoclonal Antibodies Market, by Mechanism Of Action
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. DNA Alkylating Agents
8.2.2. Microtubule Inhibitors
8.3. Bispecific Antibodies
8.3.1. Dual Checkpoint Modulators
8.3.2. T Cell Engagers
8.4. Checkpoint Inhibitors
8.4.1. CTLA-4
8.4.2. PD-1
8.4.3. PD-L1
8.5. Radioimmunotherapy
8.5.1. Alpha Emitters
8.5.2. Beta Emitters
9. Cancer Monoclonal Antibodies Market, by Target Antigen
9.1. Introduction
9.2. CD20
9.3. HER2
9.4. PD-1/PD-L1
9.5. VEGF
10. Cancer Monoclonal Antibodies Market, by Antibody Type
10.1. Introduction
10.2. Chimeric
10.3. Fully Human
10.4. Humanized
10.5. Murine
11. Cancer Monoclonal Antibodies Market, by Therapeutic Indication
11.1. Introduction
11.2. Breast Cancer
11.3. Colorectal Cancer
11.4. Lung Cancer
11.5. Lymphoma
12. Cancer Monoclonal Antibodies Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Subcutaneous
13. Cancer Monoclonal Antibodies Market, by End User
13.1. Introduction
13.2. Cancer Research Center
13.3. Contract Research Organization
13.4. Hospital
13.5. Specialty Clinic
14. Cancer Monoclonal Antibodies Market, by Formulation
14.1. Introduction
14.2. Liquid
14.3. Lyophilized Powder
15. Americas Cancer Monoclonal Antibodies Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Cancer Monoclonal Antibodies Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Roche Holding AG
18.3.2. Merck & Co., Inc.
18.3.3. Bristol-Myers Squibb Company
18.3.4. AstraZeneca PLC
18.3.5. Johnson & Johnson
18.3.6. Takeda Pharmaceutical Company Limited
18.3.7. Novartis AG
18.3.8. Eli Lilly and Company
18.3.9. Sanofi S.A.
18.3.10. Daiichi Sankyo Company, Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET MULTI-CURRENCY
FIGURE 2. CANCER MONOCLONAL ANTIBODIES MARKET MULTI-LANGUAGE
FIGURE 3. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DNA ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROTUBULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DUAL CHECKPOINT MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY T CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CTLA-4, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-L1, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HER2, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1/PD-L1, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 76. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 80. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 143. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 144. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 147. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 148. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 149. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 154. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 155. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 158. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 159. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 160. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 176. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 180. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 181. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 182. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 187. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 188. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 190. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 191. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 192. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 193. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 230. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 231. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 232. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 235. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 236. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 237. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 252. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 253. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 257. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 258. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 259. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 262. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 264. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 265. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 267. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 268. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 269. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 270. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 296. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 297. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 298. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 300. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2

Samples

Sample File DOWNLOAD NOW

Companies Mentioned

The companies profiled in this Cancer Monoclonal Antibodies market report include:
  • Roche Holding AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Eli Lilly and Company
  • Sanofi S.A.
  • Daiichi Sankyo Company, Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 88.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 163.49 Billion
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
EUR$3,750USDGBP
Antibodies Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Antibodies Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route of Administration, Distribution Channel, End User, Therapy Type - Global Forecast to 2030 - Product Image

Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route of Administration, Distribution Channel, End User, Therapy Type - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2025-2033 - Product Image

Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2025-2033

  • Report
  • 147 Pages
  • Global
From
EUR$2,999USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more